Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus CAG for relapsed/refractory T-cell lymphoma or T-ALL
ChiCTR2000039465Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine in non-Hodgkin lymphoma, T-cell and acute lymphoblastic leukemia (ALL), sponsored by The Second Xiangya Hospital. Primary endpoints: Overall response rate (ORR), Agranulocytosis time and 2 more. Started Nov 2020; status: recruiting.
02
Drugs
azacitidine
03
Conditions
non-Hodgkin lymphoma, T-cellacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2000039465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039465.